Issues

The multinational pediatric precision oncology INFORM registry identified subgroups of patients benefiting with improved progression free survival, refinement of diagnosis, and identification of hereditary cancer predisposition syndromes.

DNA and RNA sequencing of paired primary tumor/metastases from 381 patients with metastatic breast cancer shed light on enriched genomic alterations, subtype switching, and immune cell composition, and identified new candidate biomarkers of premature lethality.

Prostate cancers that benefit most from PARP inhibition have BRCA2 alterations, with BRCA2 homozygous loss associating with the longest benefit; biallelic loss of PALB2 and ATM can also sensitize to PARP inhibition.

Surface IL1RAP maintains cyst(e)ine and glutathione pools to block anoikis and facilitate metastatic dissemination in Ewing sarcoma, and minimal expression in normal tissues nominates IL1RAP as a promising immunotherapy target.

Genetic screening revealed a novel function for MCAD in glioblastoma, where in addition to its energetic role, it prevents toxic lipid accumulation, and targeting MCAD causes irreversible damage and cell death in glioblastoma cells, while sparing normal cells.

Leukemia cells evade immune control by engaging the AXL receptor tyrosine kinase in innate immune cells; targeting AXL lifts the innate immune barriers, triggers lymphocyte-mediated leukemic clearance, and elicits response to adaptive checkpoint therapy.